We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Integrating Multiple Protein Markers Predicts Health Outcomes in Chronic Kidney Disease Patients

By LabMedica International staff writers
Posted on 29 Oct 2024

Previous attempts to discover novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have generally focused on evaluating proteins individually, which limits their prognostic capability. More...

Now, a research team has developed and tested new dimensions of kidney health by integrating a combination of 17 urine and plasma biomarkers that have been independently linked to CKD progression.

Investigators at the NIDDK CKD Biomarkers Consortium (Bethesda, MD, USA) evaluated these biomarkers in preserved samples from 1,256 participants across two cohorts: the NIDDK Chronic Renal Insufficiency Cohort (CRIC) and the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. All participants had diabetes and CKD, which was defined as an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m². The researchers identified three health dimensions comprising ten biomarkers: systemic inflammation and filtration (plasma TNFR-1, TNFR-2, suPAR, SDMA), tubular function (urine EGF, ADMA, SDMA), and tubular damage (urine α1m, KIM-1, MCP-1).

Each of these health dimensions was found to be associated with CKD progression or mortality, independent of clinical risk factors and other indicators of kidney function. Notably, higher scores for tubular damage and lower scores for tubular function correlated with an increased risk of CKD progression in one of the studies, while elevated scores for systemic inflammation and kidney filtration were linked to a higher mortality risk in both studies.

“These findings suggest that a multi-biomarker approach could help clarify the wide variation in CKD progression trajectories among persons with diabetes by simultaneously capturing information on glomerular and tubulointerstitial compartments of the kidney,” said corresponding author Vanessa-Giselle Peschard, MD, of UCSF. “Further research will be needed to determine whether these kidney health dimensions could offer prognostic value for individual patients or could be used to monitor the response to medications that impact kidney health.”

Related Links:
CKD Biomarkers Consortium


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.